Urea Compounds Targeting SpsB Enzyme for Antibacterial Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of multi-drug resistant bacterial pathogens, particularly Staphylococcus aureus, poses a significant threat due to the lack of novel antibacterial classes since 1970, with existing antibiotics leading to resistance development and limited treatment options, necessitating the need for new antibacterial compounds that target novel cellular targets without inducing resistance.
Innovation Solution
Development of urea-based compounds that target type I signal peptidase (SpsB), a serine-endopeptidase involved in bacterial protein secretion, by activating it and stimulating its proteolysis, thereby disrupting cell-wall remodeling proteins and preventing resistance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat bacterial infections, then bacterial diseases can be treated, but resistance development occurs and treatment options become limited
Solution Approach 1:
The patent changes the molecular target parameter from conventional antibiotic targets to type I signal peptidase (SpsB), a previously unexploited bacterial enzyme. This parameter change enables new antibacterial activity against multi-drug resistant strains while avoiding resistance development, as SpsB is essential for bacterial protein secretion and cell wall remodeling.
Solution Approach 2:
The patent segments the antibacterial action into two functional components: (1) activation of SpsB proteolysis to disrupt cell-wall remodeling proteins, and (2) prevention of resistance development through targeted inhibition. This segmentation allows the compound to address multiple aspects of bacterial pathology simultaneously.
2Reliability
If novel antibacterial classes are developed to address multi-drug resistant pathogens, then treatment effectiveness improves, but development time and resource investment increase
Solution Approach 1:
The patent performs preliminary computational analysis and molecular modeling to identify SpsB as a viable target and design lead compounds before clinical translation. This preliminary action includes identifying the unique catalytic triad of SpsB and designing urea-based inhibitors that specifically activate its proteolysis function, thereby reducing development time.
Solution Approach 2:
The patent uses computational modeling to create virtual copies and simulations of the SpsB enzyme and its interaction with urea-based compounds. This allows virtual testing and optimization of compound structures before synthesis, accelerating the development process while maintaining high antibacterial activity against multi-resistant strains.
3Object-affected harmful factors
If antibiotics are used to treat bacterial infections, then infections are controlled, but harmful resistance mechanisms are induced in bacteria
Solution Approach 1:
The patent converts the harmful effect of bacterial protein secretion (which enables resistance) into a beneficial target. By activating SpsB proteolysis, the compound disrupts the secretion of virulence factors and cell wall proteins, thereby controlling infection while preventing resistance development. The enzyme's normal function is harnessed to create therapeutic effect.
Solution Approach 2:
Instead of inhibiting SpsB proteolysis (the conventional approach), the patent inverts the mechanism by activating it to stimulate proteolysis of cell-wall remodeling proteins. This inversion leads to disruption of bacterial cell wall integrity and prevents resistance development, as the enzyme's activation causes degradation of essential bacterial structures.
Data Source
AI summary
The invention relates to compounds which are suitable for treating bacterial diseases and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds and to the use of such compounds as disinfectants.